Rifaximin exerts beneficial effects independent of its ability to alter microbiota composition

Clinical and Translational Gastroenterology

Volumn 7, Issue 8, 2016, Pages E187-

  Kang, Dae J ^a   Kakiyama, Genta ^a   Betrapally, Naga S ^b   Herzog, Jeremy ^c   Nittono, Hiroshi ^d   Hylemon, Phillip B ^a   Zhou, Huiping ^a   Carroll, Ian ^b   Yang, Jing ^a   Gillevet, Patrick M ^b   Jiao, Chunhua ^a   Takei, Hajime ^d   Pandak, William M ^a   Iida, Takashi ^e   Heuman, Douglas M ^a   Fan, Sili ^f   Fiehn, Oliver ^f   Kurosawa, Takao ^g   Sikaroodi, Masoumeh ^b   Sartor, R B ^c   Bajaj, Jasmohan S ^a   more..

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b GEORGE MASON UNIVERSITY   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d Junshin Clinic Bile Acid Institute   (Japan)

^e NIHON UNIVERSITY   (Japan)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g HEALTH SCIENCES UNIVERSITY OF HOKKAIDO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMMONIA; BILE ACID; ENDOTOXIN; GLUTAMINASE; GLUTAMINE; INTERLEUKIN 1BETA; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; RIFAXIMIN; RNA 16S; UVOMORULIN;

AMINO ACID METABOLISM; AMMONIA BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIHYDROXYLATION; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; ENDOTOXEMIA; ENTERITIS; ENZYME ACTIVITY; HEPATIC ENCEPHALOPATHY; HYPERAMMONEMIA; MICROFLORA; MOUSE; NONHUMAN; POPULATION ABUNDANCE; PORPHYROMONADACEAE; PROTEIN EXPRESSION; SPECIES COMPOSITION;

EID: 85122958883     PISSN: 2155384X     EISSN: None     Source Type: Journal    
DOI: 10.1038/ctg.2016.44     Document Type: Article

References (33)

1. Pimentel M, Lembo A, Chey WD et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 2011; 364: 22 32.
2. Bajaj JS, Heuman DM, Hylemon PB et al. Altered profile of human gut microbiome is associated with cirrhosis and its complications. J Hepatol 2014; 60: 940 947.
3. Bajaj JS, Heuman DM, Sanyal AJ et al. Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy. PLoS One 2013; 8: e60042.
4. Bass NM, Mullen KD, Sanyal A et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med 2010; 362: 1071 1081.
5. Shawcross DL. Is it time to target gut dysbiosis and immune dysfunction in the therapy of hepatic encephalopathy? Expert Rev Gastroenterol Hepatol 2015; 9: 539 542.
6. Patidar KR, Thacker LR, Wade JB et al. Covert hepatic encephalopathy is independently associated with poor survival and increased risk of hospitalization. Am J Gastroenterol 2014.
7. Bajaj JS, Riggio O. Drug therapy: rifaximin. Hepatology 2010; 52: 1484 1488.
8. Soldi S, Vasileiadis S, Uggeri F et al. Modulation of the gut microbiota composition by rifaximin in non-constipated irritable bowel syndrome patients: A molecular approach. Clin Exp Gastroenterol 2015; 8: 309 325.
9. DuPont HL. Therapeutic effects and mechanisms of action of rifaximin in gastrointestinal diseases. Mayo Clin Proc 2015; 90: 1116 1124.
10. Gao J, Gillilland MG 3rd, Owyang C. Rifaximin, gut microbes and mucosal inflammation: unraveling a complex relationship. Gut Microbes 2014; 5: 571 575.
11. Vilstrup H, Amodio P, Bajaj J et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology 2014; 60: 715 735.
12. Kim SC, Tonkonogy SL, Albright CA et al. Variable phenotypes of enterocolitis in interleukin 10-deficient mice monoassociated with two different commensal bacteria. Gastroenterology 2005; 128: 891 906.
13. Zhang H, Xue Y, Wang H et al. Mast cell deficiency exacerbates inflammatory bowel symptoms in interleukin-10-deficient mice. World J Gastroenterol 2014; 20: 9106 9115.
14. Gillevet P, Sikaroodi M, Keshavarzian A et al. Quantitative assessment of the human gut microbiome using multitag pyrosequencing. Chem Biodivers 2010; 7: 1065 1075.
15. Segata N, Izard J, Waldron L et al. Metagenomic biomarker discovery and explanation. Genome Biol 2011; 12: R60.
16. Bajaj JS, Ridlon JM, Hylemon PB et al. Linkage of gut microbiome with cognition in hepatic encephalopathy. Am J Physiol Gastrointest Liver Physiol 2012; 302: G168 G175.
17. Kakiyama G, Muto A, Takei H et al. A simple and accurate HPLC method for fecal bile acid profile in healthy and cirrhotic subjects: validation by GC-MS and LC-MS. J Lipid Res 2014; 55: 978 990.
18. Miller KE, Balbas JC, Benton RL et al. Glutaminase immunoreactivity and enzyme activity is increased in the rat dorsal root ganglion following peripheral inflammation. Pain Res Treat 2012; 2012: 414697.
19. Fiehn O, Barupal DK, Kind T. Extending biochemical databases by metabolomic surveys. J Biol Chem 2011; 286: 23637 23643.
20. Romero-Gomez M, Jover M, Galan JJ et al. Gut ammonia production and its modulation. Metab Brain Dis 2009; 24: 147 157.
21. Shawcross DL, Davies NA, Williams R et al. Systemic inflammatory response exacerbates the neuropsychological effects of induced hyperammonemia in cirrhosis. J Hepatol 2004; 40: 247 254.
22. Butterworth RF, Norenberg MD, Felipo V et al. Experimental models of hepatic encephalopathy: ISHEN guidelines. Liver Int 2009; 29: 783 788.
23. Romero-Gomez M. Role of phosphate-Activated glutaminase in the pathogenesis of hepatic encephalopathy. Metab Brain Dis 2005; 20: 319 325.
24. Llopis M, Cassard AM, Wrzosek L et al. Intestinal microbiota contributes to individual susceptibility to alcoholic liver disease. Gut 2016; 65: 830 839.
25. Natividad JM, Pinto-Sanchez MI, Galipeau HJ et al. Ecobiotherapy rich in firmicutes decreases susceptibility to colitis in a humanized gnotobiotic mouse model. Inflamm Bowel Dis 2015; 21: 1883 1893.
26. Ridlon JM, Kang DJ, Hylemon PB. Bile salt biotransformations by human intestinal bacteria. J Lipid Res 2006; 47: 241 259.
27. Islam KB, Fukiya S, Hagio M et al. Bile acid is a host factor that regulates the composition of the cecal microbiota in rats. Gastroenterology 2011; 141: 1773 1781.
28. Xu D, Gao J, Gillilland M 3rd et al. Rifaximin alters intestinal bacteria and prevents stressinduced gut inflammation and visceral hyperalgesia in rats. Gastroenterology 2014; 146: 484 96 e4.
29. Stenman LK, Holma R, Eggert A et al. A novel mechanism for gut barrier dysfunction by dietary fat: epithelial disruption by hydrophobic bile acids. Am J Physiol Gastrointest Liver Physiol 2013; 304: G227 G234.
30. Ma X, Shah YM, Guo GL et al. Rifaximin is a gut-specific human pregnane X receptor activator. J Pharmacol Exp Ther 2007; 322: 391 398.
31. Mencarelli A, Renga B, Palladino G et al. Inhibition of NF-kappaB by a PXR-dependent pathway mediates counter-regulatory activities of rifaximin on innate immunity in intestinal epithelial cells. Eur J Pharmacol 2011; 668: 317 324.
32. Zhu Q, Zou L, Jagavelu K et al. Intestinal decontamination inhibits TLR4 dependent fibronectin-mediated cross-Talk between stellate cells and endothelial cells in liver fibrosis in mice. J Hepatol 2012; 56: 893 899.
33. Kang DJ, Betrapally NS, Ghosh SA et al. Gut microbiota drive the development of neuroinflammatory response in cirrhosis. Hepatology; advance online publication, 23 June 2016; doi: 10.1002/hep.28696